NCT06922331 - Upadacitinib for Refractory IBD in Asian Children and Elderly: Age-Stratified Analysis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

March 1, 2025

Conditions

Crohn's Disease (CD)Ulcerative Colitis (UC)Refractory Crohn's DiseaseRefractory Ulcerative ColitisInflammatory Bowel Disease (IBD)Pediatric Crohn's DiseaseGeriatric Ulcerative Colitis

Interventions

DRUG

Upadacitinib

A selective Janus kinase (JAK) 1 inhibitor used for the treatment of refractory inflammatory bowel disease.

Trial Locations (1)

515000

The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors

lead

Sixth Affiliated Hospital, Sun Yat-sen University

OTHER